Regeneron (NASDAQ:REGN) reported positive Phase 2 data for its thrombosis drug candidates REGN7508 and REGN9933 and plans to ...

A pair of Regeneron’s monoclonal antibodies have held their own against a commonly used anticoagulant in a phase 2 trial, ...

FDA confirms end of Zepbound shortage, but announces new shortages for other medications, including Humira biosimilar and painkillers. Details here.

They found this true for antihypertensives, lipid-lowering drugs, oral anticoagulants, and diuretics. However, they found that short-term use of 1 to 4 years of all cardiovascular medication ...

INR:6936. sports free streaming Xinlitai will take over 2.5 billion anticoagulant drug original drug market New news on the fourth round of national procure ...

The company is planning a “broad Phase 3 program” for two anticoagulants after they outperformed marketed medicines in a pair ...

These drugs included: Combining antihypertensives with lipid-lowering medications, diuretics, or oral anticoagulants for 5 years or more was also associated with a reduced risk. In contrast ...